Tags

Type your tag names separated by a space and hit enter

[2018 Chinese guideline for the diagnosis and treatment of rheumatoid arthritis].
Zhonghua Nei Ke Za Zhi. 2018 Apr 01; 57(4):242-251.ZN

Abstract

To develop a new evidence-based diagnosis, treatment guideline for rheumatoid arthritis (RA) in China.A multidisciplinary guideline development group was established. The grading of recommendations assessment, development and evaluation (GRADE) system was used to rate the quality of evidence and the strength of recommendations. Recommendations were derived from evidence body, the balance of benefits and harmsand patient's values and preferences.The guideline development group developed 10 recommendations for the diagnosis and treatment of RA. The guideline covered the classification criteria, disease activity monitoring and assessing, antirheumatic drugs (DMARDs) and glucocorticoids with treat-to-target approach of RA.This rheumatoid arthritis guideline was intended to serve as a tool for clinicians and patients for best decisions-making in China.

Authors

No affiliation info available

Pub Type(s)

Journal Article

Language

chi

PubMed ID

29614581

Citation

Chinese Rheumatology Association. "[2018 Chinese Guideline for the Diagnosis and Treatment of Rheumatoid Arthritis]." Zhonghua Nei Ke Za Zhi, vol. 57, no. 4, 2018, pp. 242-251.
Chinese Rheumatology Association. [2018 Chinese guideline for the diagnosis and treatment of rheumatoid arthritis]. Zhonghua Nei Ke Za Zhi. 2018;57(4):242-251.
Chinese Rheumatology Association. (2018). [2018 Chinese guideline for the diagnosis and treatment of rheumatoid arthritis]. Zhonghua Nei Ke Za Zhi, 57(4), 242-251. https://doi.org/10.3760/cma.j.issn.0578-1426.2018.04.004
Chinese Rheumatology Association. [2018 Chinese Guideline for the Diagnosis and Treatment of Rheumatoid Arthritis]. Zhonghua Nei Ke Za Zhi. 2018 Apr 1;57(4):242-251. PubMed PMID: 29614581.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [2018 Chinese guideline for the diagnosis and treatment of rheumatoid arthritis]. A1 - ,, PY - 2018/4/4/entrez PY - 2018/4/5/pubmed PY - 2018/5/29/medline KW - Arthritis, rheumatoid KW - Diagnosis KW - Guideline KW - Therapy SP - 242 EP - 251 JF - Zhonghua nei ke za zhi JO - Zhonghua Nei Ke Za Zhi VL - 57 IS - 4 N2 - To develop a new evidence-based diagnosis, treatment guideline for rheumatoid arthritis (RA) in China.A multidisciplinary guideline development group was established. The grading of recommendations assessment, development and evaluation (GRADE) system was used to rate the quality of evidence and the strength of recommendations. Recommendations were derived from evidence body, the balance of benefits and harmsand patient's values and preferences.The guideline development group developed 10 recommendations for the diagnosis and treatment of RA. The guideline covered the classification criteria, disease activity monitoring and assessing, antirheumatic drugs (DMARDs) and glucocorticoids with treat-to-target approach of RA.This rheumatoid arthritis guideline was intended to serve as a tool for clinicians and patients for best decisions-making in China. SN - 0578-1426 UR - https://www.unboundmedicine.com/medline/citation/29614581/[2018_Chinese_guideline_for_the_diagnosis_and_treatment_of_rheumatoid_arthritis]_ L2 - http://journal.yiigle.com/LinkIn.do?linkin_type=pubmed&issn=0578-1426&year=2018&vol=57&issue=4&fpage=242 DB - PRIME DP - Unbound Medicine ER -